Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
National Clinical Research Center for Cancer, Tianjin, China.
J Leukoc Biol. 2022 Dec;112(6):1591-1603. doi: 10.1002/JLB.5MA0322-746R. Epub 2022 May 2.
IL-33, an epithelial-derived cytokine, functions as an alarmin for the immune system in the tumor microenvironment (TME). However, the expression and role of IL-33 on cervical cancer remain unclear. The aim of this study was to investigate the expression of IL-33 and its relationship with clinicopathologic features, tertiary lymphoid structures (TLS), and programmed cell death 1 (PD-1)/programmed cell death 1 ligand (PD-L1) immune checkpoints by immunohistochemistry in 93 cervical cancer patient specimens. Down-regulation of IL-33 expression was observed in tumor tissues compared with adjacent tissues. More importantly, IL-33 was detected in the cytoplasm of tumor fraction. IL-33 expression in tumor cytoplasm was associated with tumor size and the invasive depth of tumors (p < 0.05). Meanwhile, IL-33 expression in tumor cytoplasm was positively correlated with infiltration of CD3 T cells, CD8 T cells, and PD-L1 expression in tumor tissues (p < 0.05). The number of TLS strongly correlated with the depth of tumor invasion, preoperative chemotherapy, human papillomavirus infection, and high level of PD-1 (p < 0.05). However, there was no significant relationship between IL-33 and TLS. Kaplan-Meier survival curves showed that the formation of TLS was associated with a better prognosis (p = 0.008). In multivariable Cox regression modeling, high expression of PD-L1 in tumor tissues was correlated with poor prognosis (HR = 0.128; 95% CI: 0.026-0.646; p = 0.013), whereas the high expression of IL-33 in tumor tissues was associated with better prognosis (HR = 5.097; 95% CI:1.050-24.755; p = 0.043). These results indicate that IL-33, TLS, and PD-L1 are potentially valuable prognostic predictor for cervical cancer. IL-33 has potential for combination with PD-L1-related antitumor therapy.
白细胞介素 33(IL-33)是一种上皮细胞衍生的细胞因子,作为肿瘤微环境(TME)中免疫系统的警报素发挥作用。然而,IL-33 在宫颈癌中的表达和作用尚不清楚。本研究旨在通过免疫组织化学方法检测 93 例宫颈癌患者标本中 IL-33 的表达及其与临床病理特征、三级淋巴结构(TLS)和程序性细胞死亡 1(PD-1)/程序性细胞死亡配体 1(PD-L1)免疫检查点的关系。与相邻组织相比,肿瘤组织中观察到 IL-33 表达下调。更重要的是,IL-33 存在于肿瘤细胞的细胞质中。肿瘤细胞质中 IL-33 的表达与肿瘤大小和肿瘤浸润深度相关(p<0.05)。同时,肿瘤组织中 IL-33 表达与肿瘤组织中 CD3 T 细胞、CD8 T 细胞和 PD-L1 浸润呈正相关(p<0.05)。TLS 的数量与肿瘤浸润深度、术前化疗、人乳头瘤病毒感染和高水平 PD-1 强烈相关(p<0.05)。然而,IL-33 与 TLS 之间没有显著关系。Kaplan-Meier 生存曲线表明,TLS 的形成与更好的预后相关(p=0.008)。在多变量 Cox 回归模型中,肿瘤组织中 PD-L1 的高表达与预后不良相关(HR=0.128;95%CI:0.026-0.646;p=0.013),而肿瘤组织中 IL-33 的高表达与更好的预后相关(HR=5.097;95%CI:1.050-24.755;p=0.043)。这些结果表明,IL-33、TLS 和 PD-L1 可能是宫颈癌有价值的预后预测指标。IL-33 具有与 PD-L1 相关的抗肿瘤治疗联合的潜力。